Skip to main content

Table 1 Clinicopathological characteristics of 7478 Korean patients who met the Z0011 criteria

From: Impact of the ACOSOG Z0011 trial on surgical practice in Asian patients: trends in axillary surgery for breast cancer from a Korean Breast Cancer Registry analysis

  Total number (n = 7478) SLNB + ALND (n = 4834) SLNB alone (n = 2644) p valuea
Age at surgery (years)
  < 40 767 (10.3) 486 (10.1) 281 (10.6) 0.738
 40–49 2755 (36.9) 1790 (37.0) 965 (36.6)
 50–59 2482 (33.2) 1612 (33.4) 870 (33.0)
 60–69 1060 (14.2) 690 (14.3) 370 (14.0)
 70–79 360 (4.8) 227 (4.7) 133 (5.0)
  > 80 48 (0.6) 27 (0.5) 21 (0.8)
 Unknown 6 2 4
Year of surgery
 2011 1113 853 (76.6) 260 (23.4)  < 0.0001
 2012 1252 909 (72.6) 343 (27.4)
 2013 1278 891 (69.7) 387 (30.3)
 2014 1241 784 (63.2) 457 (36.8)
 2015 801 487 (60.8) 314 (39.2)
 2016 727 394 (54.2) 333 (45.8)
 2017 784 382 (48.7) 402 (51.3)
 2018 282 134 (47.5) 148 (52.5)
pT
 pT1 4156 (55.6) 2490 (51.5) 1666 (63.0)  < 0.0001
 pT2 3322 (44.4) 2344 (48.5) 978 (37.0)
 Number of resected nodes (median, range) 12 (1–57) 16 (5–57) 5 (1–16)  < 0.0001
 Number of positive lymph nodes (median, range) 1 (1–25) 2 (1–25) 1 (1–3)  < 0.0001
pN
 pN1 6381 (85.3) 3779 (78.2) 2602 (98.4)  < 0.0001
 pN2 863 (11.5) 827 (17.1) 36 (1.4)
 pN3 234 (3.2) 228 (4.7) 6 (0.2)
Multifocality
 Single lesion 5362 (91.7) 3407 (91.2) 1955 (92.5) 0.094
 Multifocal lesion 487 (8.3) 328 (8.8) 159 (7.5)
 Unknown 1629 1099 530
Histologic subtype
 IDC 6232 (83.3) 4067 (84.1) 2165 (81.9) 0.013
 Other 1246 (16.7) 767 (15.9) 479 (18.1)
Histologic grade
 I 915 (13.8) 600 (14.0) 315 (13.5)  < 0.0001
 II 3605 (54.6) 2235 (52.3) 1370 (58.9)
 III 2085 (31.6) 1442 (33.7) 643 (27.6)
 Unknown 873 557 316
Lymphatic invasion
 No 2899 (50.8) 1731 (46.9) 1168 (57.8)  < 0.0001
 Yes 2811 (49.2) 1958 (53.1) 853 (42.2)
 Unknown 1768 1145 623
ER status
 Negative 1212 (18.0) 843 (19.3) 369 (15.5)  < 0.0001
 Positive 5534 (82.0) 3516 (80.7) 2018 (84.5)
 Unknown 732 475 257
HER2 status
 Negative 5180 (83.2) 3299 (81.9) 1881 (85.5)  < 0.001
 Positive 1047 (16.8) 728 (18.1) 319 (14.5)
 Unknown 1251 807 444
ER/HER2 status
 ER + /HER2- 4450 (71.5) 2794 (69.4) 1656 (75.3)  < 0.0001
 HER2 +  1047 (16.8) 728 (18.1) 319 (14.5)
 ER-/HER2- 729 (11.7) 505 (12.5) 224 (10.2)
 Unknown 1252 807 445
TNBC
 Yes 670 (10.1) 460 (10.7) 210 (8.9) 0.021
 No 5984 (89.9) 3839 (89.3) 2145 (91.1)
 Unknown 824 535 289
Radiotherapy
 Yes 5697 (93.5) 3649 (93.7) 2048 (93.0) 0.317
 No 398 (6.5) 245 (6.3) 153 (7.0)
 Unknown 1383 940 443
  1. SLNB Sentinel lymph node biopsy, ALND Axillary lymph node dissection, pT Pathologic tumor stage, IDC Invasive ductal carcinoma, ER Estrogen receptor, HER2 Human epidermal growth factor receptor 2
  2. aCategorical variables are tested by chi-square test and non-normally distributed numerical variables are tested by Wilcoxon rank-sum test